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Influenza A pandemic (H1N1) 2009 virus RNA was de-
tected by reverse transcription–PCR in 144 clinical samples 
from Bonn, Germany. A common rapid antigen–based test 
detected the virus in only 11.1% of these samples. The para-
mount feature of rapid test–positive samples was high virus 
concentration. Antigen-based rapid tests appear unsuitable 
for virologic diagnostics in the current pandemic.
I
n April 2009, a novel human influenza virus A (H1N1) 
variant, influenza A pandemic (H1N1) 2009 virus, was 
identified in Mexico and the United States (1). Efficient 
human-to-human transmission facilitated global spread of 
this virus. On June 11, 2009, the World Health Organiza-
tion (WHO) raised its pandemic alert level to Phase 6, indi-
cating ongoing pandemic transmission. By July 27, WHO 
had registered 134,503 laboratory-confirmed cases and 816 
confirmed deaths caused by pandemic (H1N1) 2009 virus 
infection worldwide (2).
In Germany, 5,324 cases were confirmed by July 30 
(3). Almost 50% (n = 2,184) of these cases occurred in the 
federal state of North Rhine-Westphalia in western Ger-
many, where our institution is located. As of July 30, we 
had tested 1,838 suspected cases and confirmed 221. All 
testing was based on real-time reverse transcription–PCR 
(RT-PCR) specific for the hemagglutinin (HA) gene of pan-
demic (H1N1) 2009 virus in clinical specimens. Although 
the real-time RT-PCR format provides considerably de-
creased turnaround times in molecular diagnostics, delays 
associated with shipping of samples and laboratory-based 
testing are a concern when many patients have to be seen 
in short time. Antigen-based rapid assays can be used as 
bedside tests and have been successfully applied in studies 
of influenza caused by the seasonal strains A (H1N1) and 
A (H3N2) (4).
The Study
To evaluate the clinical applicability of a widely dis-
tributed rapid test in patients with pandemic (H1N1) 2009 
virus, we retrospectively tested 144 PCR-positive clinical 
specimens from 144 different patients with the BinaxNOW 
Influenza A&B Rapid Test (Inverness Medical, Cologne, 
Germany). The assay uses monoclonal antibodies directed 
against the influenza A and B nucleoproteins (NP).
During preanalytical preparation, all of our samples 
(nasal and throat swabs) had been eluted from the swab 
in 500 µL of 0.9% sodium chloride solution and used for 
RNA extraction. The remaining part of the suspension was 
immediately stored at −70°C until use in this study. Before 
inclusion in the study, presence of pandemic (H1N1) 2009 
virus in RNA extracts of all 144 samples was confirmed 
with a second pandemic (H1N1) 2009 virus–specific real-
time RT-PCR targeting the matrix gene. Virus concentra-
tions in samples were determined from the RNA extract 
without thawing the original sample, using real-time RT-
PCR for the HA gene. Absolute quantification was done 
using photometrically quantified RNA in vitro transcripts, 
according to methodology described earlier (5).
The  BinaxNOW  assay  was  used  exactly  according 
to the manufacturer’s instructions on 100 µL of freshly 
thawed  original  sample.  Of  144  PCR-confirmed  cases, 
only 16 could be detected by using the rapid antigen–based 
test, corresponding to a sensitivity of merely 11.1% (95% 
confidence interval 6.7–17.7). Samples that yielded posi-
tive results in the rapid test had a median concentration of 
4,570,880 RNA copies/mL of suspension (range 5,370–74-
,131,020)  (Figure).  This  contrasted  with  20,089  (range 
120–64,565,420)  median  viral  RNA  copies  in  the  rapid 
test–negative group. This difference was highly significant 
at p<0.001 (1-way analysis of variance [ANOVA], F = 
38.824, done on logarithmic RNA concentrations).
The BinaxNOW rapid antigen–based assay was used 
in  our  institution  during  the  preceding  2  influenza  sea-
sons (2007–08 and 2008–09). The 2007–08 epidemic was 
driven almost exclusively by seasonal influenza virus A 
(H1N1) in Germany, whereas the 2008–09 epidemic was 
mostly caused by influenza virus A (H3N2) (6). The sen-
sitivity of BinaxNOW in comparison with a standard RT-
PCR assay (7) was 37.5% (6 rapid test positives in 16 PCR 
positives) and 51.9% (14 rapid test positives in 27 PCR 
positives) in the influenza seasons 2007–08 and 2008–09, 
respectively. These results agree with published data on the 
application of BinaxNow and other rapid antigen–based 
tests (8–10). Similar to pandemic (H1N1) 2009 virus, vi-
rus concentration was the main determinant for a positive 
rapid test during both earlier influenza seasons, although 
slightly less marked than in the current pandemic (2007–
08, median RNA copies/mL 74,131,020 [range 3,981,070– 
8,709,635,900]  and  346,740  [range  2,450–5,495,410]  in 
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rapid  test–positive  vs.  –negative  patients,  respectively 
[1-way ANOVA, p<0.001, F = 21.127]; 2008–09, median 
RNA  copies  19,498,446  [range  138,040–1,737,800,830] 
and  120,230  [range  38,900–100,000,000]  in  rapid  test–
positive  versus  –negative  patients,  respectively  [1-way 
ANOVA, p = 0.001, F = 15.659]).
Conclusions
Because children tend to have higher influenza virus 
shedding than adults, the overall better sensitivity of the 
antigen-based rapid test in preceding influenza A seasons 
might be due to sample selection effects because the cur-
rent pandemic leads to higher percentages of adult sam-
ples than does regular seasons. The median age in our co-
hort was 18 years (range 1–59 years), with no significant 
age difference between rapid test–positive and –negative   
patients (1-way ANOVA, p = 0.246, F = 1.356). Most of 
the samples from earlier influenza A seasons originated 
from children <7 years of age (2008, median 3 years, range 
1–17 years; 2009, median 4 years, range 1–67 years).
In agreement with our study, a recent report by Faux 
at al. on the detection of pandemic (H1N1) 2009 virus by 
rapid  antigen  test  found  low  clinical  sensitivity  for  the 
QuickVue Influenza assay (Quidel, San Diego, CA, USA) 
in comparison to RT-PCR (11). These authors found clini-
cal sensitivity of QuickVue to be ≈51%. Notably, earlier 
studies on seasonal influenza have identified 27% clinical 
sensitivity for the same assay in comparison to RT-PCR 
(12), and the higher sensitivity for pandemic (H1N1) 2009 
virus observed by Faux et al. might be due either to a rather 
small sample size in this early study (39 patients) or a dif-
ferent composition of the cohort (military personnel) as op-
posed to our study. Nevertheless, our clinical observations 
are supported by recent reports suggesting low analytical 
sensitivity of antigen-based assays on cultured pandemic 
(H1N1) 2009 virus (13,14) and clinical material analyzed 
using 2 different antigen-based rapid tests, virus culture, 
and a Luminex-based multiplex assay (15). A synopsis of 
data suggests clearly that testing of patients suspected of 
pandemic (H1N1) 2009 infection with antigen-based as-
says may produce misleading results in clinical practice. 
Application of such assays should be discouraged in favor 
of continued molecular diagnostics.
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